Abstract
Leprosy is a chronic granulomatous infectious disease that attacks the peripheral nerves, skin, and other organs. The cytokine IL-10 can deactivate macrophages, inhibit IL-12 production, which also inhibits IFN-ϒ production. IL-10 directly inhibits CD4+T cells and antigen-presenting cell (APC) function in cells infected with M. leprae. The purpose of this study was to determine the differences in IL-10 levels in leprosy patients and non-patients at dr. Mohammad Hoesin Palembang Hospital. This study used a case-control design for comparing 2 groups. Respondents in this study were 80 people. The case samples were all leprosy patients who were treated at the dr. Mohammad Hoesin Hospital, Palembang for the period of January 16 - February 16, 2019, while the control group was medical personnel and paramedics who worked at the same hospital. The examination was carried out using the ELISA Sandwich method. The results showed that there was a significant difference in IL-10 levels between leprosy patients and non-leprosy leprosy (p=0.000). The average IL-10 level in leprosy patients (13.24 pg/ml) was lower than that in non-patients (40.15 pg/ml). It is concluded that there is a difference in IL-10 levels between leprosy patients and non-leprosy patients in leprosy sufferers are lower than non-leprosy persons.
Highlights
Morbus Hansen (Leprosy) is a chronic infection that attacks the peripheral nerves, skin and other organs.[1]
Bivariate Analysis A bivariate analysis was performed to determine the difference in serum interleukin 10 (IL-10) levels between the case and the control group
Administration of multi drug therapy (MDT) could result in suppression of bacterial index as well as reduced stimulation of specific immune response resulting in reduction of cytokines production among people with leprosy
Summary
Morbus Hansen (Leprosy) is a chronic infection that attacks the peripheral nerves, skin and other organs.[1]. The etiology of leprosy, the Mycobacterium leprae, is an acid-resistant, gram-positive, rod-shaped, obligate-aerobic bacteria which cannot be cultured on artificial intra cellular media. This microorganism was first discovered by Gerhard Armauer Hansen in 1873.3. According to WHO data (2016), leprosy cases have increased from 211.973 in 2015 to 214.783 in 2016. As many as 94% of leprosy cases reported in only 14 countries with >1000 new cases annually. Southeast Asia is the region with the third highest leprosy burden in the world in 2015 with a total of 156.118 cases. In Indonesia, leprosy cases were reported to be 17.025 and 17.202 in 2014 and 2015, respectively
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
